Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes
Main finding · Composite of MI, stroke and all-cause deathResult — go to the resultHazard ratio 0.85 95% CI 0.74–0.98Authors' conclusion
Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C-lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.
Study context
- Population
- Patients aged ≥20 years with T2D and dyslipidemia, Korean National Health Insurance claims database
- Exposure
- Low- or moderate-intensity statin plus ezetimibe vs high-intensity statin monotherapy
- Outcome
- Composite of:
- Myocardial infarction (MI)
- Stroke
- All-cause death (primary prevention)
Methodological detailspropensity score-matched, Korean National Health Insurance claims database
- Propensity score-matched
- Korean National Health Insurance claims database
Main finding
Composite of:
Hazard ratio
0.85
95% CI 0.74–0.98
Moderate-intensity statin + ezetimibevs High-intensity statin
HR 0.85 (95% CI 0.74–0.98)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Moderate-intensity statin + ezetimibe | High-intensity statin | P value |
|---|---|---|---|
| LDL-CModerate-intensity statin + ezetimibe vs High-intensity statin · lower with moderate-intensity statin + ezetimibe | 74 ± 37.9 mg/dL | 80.8 ± 38.8 mg/dL | P < 0.001 |
Low-density lipoprotein cholesterol (LDL-C)
- No significant difference in LDL-C between low-intensity statin + ezetimibe and high-intensity statin
Original publication
Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes. J Clin Endocrinol Metab. Published 4 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →